Physician profile
Julia Mcmath Stewart
NPI 1538303888
$2,622.34
in general payments reported to CMS, 2019-2025
29 companies · $490 in 2025
The $490 reported for 2025 was more than what 93% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $179 · 2021: $148 · 2022: $504 · 2023: $399 · 2024: $440 · 2025: $490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,328.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $561.78 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $275.74 | 2019-2024 | Jornay Pm |
| Neos Therapeutics, LP | $201.17 | 2019-2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Sobi, INC | $183.46 | 2019-2023 | |
| Pfizer INC. | $180.98 | 2019-2024 | |
| Collegium Pharmaceutical, INC. | $144.90 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $136.12 | 2019-2025 | Vaxelis, Gardasil 9, Vaxneuvance |
| Welch Allyn | $117.60 | 2021 | |
| Baxter Healthcare | $117.60 | 2022 | |
| Tris Pharma INC | $92.88 | 2019-2024 | Dyanavel Xr |
| Sanofi Pasteur INC. | $74.96 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.95 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $50.96 | 2022-2025 | Qelbree, Qelbree |
| Hologic Sales and Service, LLC | $49.59 | 2022-2024 | Aptima |
| Verrica Pharmaceuticals INC. | $48.37 | 2024-2025 | Ycanth |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $47.07 | 2025 | |
| Vertical Pharmaceuticals, LLC | $37.31 | 2025 | Relexxii |
| Astrazeneca Pharmaceuticals LP | $30.24 | 2023-2024 | Flumist Quadrivalent |
| Glaxosmithkline, LLC. | $28.34 | 2019-2020 | |
| Kaleo, INC. | $27.26 | 2019 | |
| Acadia Pharmaceuticals INC | $23.48 | 2024 | Daybue |
| Noven Pharmaceuticals, INC. | $20.36 | 2024 | Xelstrym |
| Mission Pharmacal Company | $18.54 | 2019 | |
| Organon LLC | $17.60 | 2025 | |
| Rhodes Pharmaceuticals L.P. | $17.07 | 2019 | |
| Noven Therapeutics, LLC | $17.04 | 2024 | Xelstrym |
| Adlon Therapeutics L.P. | $11.96 | 2020 | |
| Genentech USA, INC. | $11.86 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Stewart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.